Regulatory

Part:BBa_K3249009

Designed by: Omar El-Fahmawi   Group: iGEM19_UC_Davis   (2019-10-21)


CRY2-VP64

This part is composed of Cryptochrome 2 (CRY2) photoreceptor linked to a VP64 transcriptional activator intended for use in the light activated CRISPR/Cas9 effector system (LACE). When induced by blue light, CRY2 dimerizes with its binding partner CIBN, effectively bringing the transcriptional activator VP64 to the target site defined by the dCas9/gRNA complex. gRNAs can be designed in order for the dCas9 protein to target and increase transcription of specific genes. A figure of how the system works is shown below.

Figure 1:
Light activation triggers the dimerization of CRY2 to CIBN, which brings the activator VP64 to the promoter region of the GOI increasing rate of transcription.

Characterization

We used lipofectamine to transiently cotransfect CHO cells with 2 plasmids. One containing CIBN-dCas9-CIBN and our 3 gRNAs and the other containing CRY2-VP64. When both plasmids are successfully transfected into the cells we expect to see an increase in transcription for the gene IL1RN when the cells are induced by blue light. The cells were incubated at 37° C for 24 hours to allow them to adhere to the 24 well plate. After 24 hours, they were placed into our light plate apparatus (LPA) while still being incubated at 37°C. The LPA illuminated the wells with blue light for 24 hours. We then extracted the RNA from the CHO cells and used reverse transcriptase to convert this RNA into cDNA. Using the cDNA as template DNA, qPCR was performed to quantify the fold increase of IL1RN expression compared to untreated cells. The data below compares the effectiveness of our CRY2-VP64 to NEU China 2016s CRY2-VP64 (Part:BBa_K1982010) and another activator CRY2-VPR.

Figure 1:
Fold expression of IL1RN in CHO cells when transfected with different transcriptional activators.

Fold increase was calculated using the delta-delta Ct method for qPCR. All data was normalized to the reference genes recommended by MIQE guidelines and fold increase was compared to untransfected cells. For more information about our experimental design and data analysis refer to our wiki (https://2019.igem.org/Team:UC_Davis).

Sequence and Features


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Illegal EcoRI site found at 723
    Illegal PstI site found at 533
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal EcoRI site found at 723
    Illegal NheI site found at 1855
    Illegal PstI site found at 533
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal EcoRI site found at 723
    Illegal BglII site found at 393
    Illegal BglII site found at 852
    Illegal BamHI site found at 1331
    Illegal BamHI site found at 1846
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal EcoRI site found at 723
    Illegal PstI site found at 533
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal EcoRI site found at 723
    Illegal PstI site found at 533
    Illegal AgeI site found at 277
    Illegal AgeI site found at 1006
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI site found at 629
    Illegal BsaI.rc site found at 38
    Illegal SapI.rc site found at 146


[edit]
Categories
Parameters
None